Clinical Oncology
Volume 22, Issue 6 , Pages 395-404 , August 2010

Thyroid Cancer Epidemiology and Prognostic Variables

  • J.A. Sipos

      Affiliations

    • Division of Endocriniology, Ohio State University, Columbus, OH, USA
    • Corresponding Author InformationAuthor for correspondence: J.A. Sipos, 1581 Dodd Drive, Columbus, OH 43210, USA. Tel: +1 614 292 3800; Fax: +1 614 292 1550.
    • ,
  • E.L. Mazzaferri

      Affiliations

    • Division of Endocriniology, Ohio State University, Columbus, OH, USA
    • Division of Endocrinology, University of Florida, Gainesville, FL, USA

Received 4 February 2010 ,Revised 9 March 2010 ,Accepted 4 May 2010.

References 

  1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83:2638–2648
  2. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17–44
  3. American Cancer Society . Cancer facts and figures 2009. Available at: http://www.cancer.org(last accessed 25 January 2010)
  4. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Ver. 1.0. IARC Cancer Base No. 5. Lyon: IARC Press; 2001;Available at: http://www-dep.iarc.fr/globocan/globocan.html(last accessed 2 March 2010)
  5. Kosary CL. Cancer of the thyroid. In:  Ries LAG,  Young JL,  Keel GE,  Eisner MP,  Lin YD,  Horner MJ editor. SEER survival monograph: cancer survival among adults. U.S. SEER program, 1988–2001, patient and tumor characteristics. Bethesda, MD: National Cancer Institute, SEER Program, NIH; 2007;
  6. Ries LAG, Harkins D, Krapcho D, et al. SEER Cancer statistics review, 1997–2003. Available at: http://seer.cancer.gov/csr/1975_2001/results_merged/sect_25_thyroid.pdf(last accessed 7 January 2010)
  7. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control. 2009;20:525–531
  8. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer statistics review, 1975–2001. Bethesda, MD: National Cancer Institute; 2010;Available at: http://seer_cancer.gov/csr/1975_2001/(last accessed 25 January 2010)
  9. Colonna M, Grande E, Jonasson JG Eurocare Working Group. Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983–1994 (EUROCARE-3 study). Eur J Cancer. 2006;42:2598–2608
  10. Horner MJ, Ries LAG, Krapcho M, et al. SEER stat fact sheets. Bethesda, MD: National Cancer Institute; 2009;Available at: http://seer.cancer.gov/statfacts/html/thyro.html(last accessed 25 January 2010)
  11. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167
  12. de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocr Pathol. 2006;17:165–173
  13. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol. 2005;26:87–90
  14. Yoshimoto Y, Ezaki H, Etoh R, Hiraoka T, Akiba S. Prevalence rate of thyroid diseases among autopsy cases of the atomic bomb survivors in Hiroshima, 1951–1985. Radiat Res. 1995;141:278–286
  15. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–791
  16. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–3807
  17. Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid. 2009;19:333–340
  18. Mazzaferri EL. Managing small thyroid cancers. JAMA. 2006;295:2179–2182
  19. Chem KT, Rosai J. Follicular variant of thyroid papillary carcinoma: a clinicopathologic study of six cases. Am J Surg Pathol. 1977;1:123–130
  20. Clavel-Chapelon F, Guillas G, Tondeur L, Kernaleguen C, Boutron-Ruault MC. Risk of differentiated thyroid cancer in relation to adult weight, height, and body shape over life: the French E3N cohort. Int J Cancer. 2010;126(12):2984–2990
  21. Zielinski JM, Garner MJ, Band PR, et al. Health outcomes of low-dose ionizing radiation exposure among medical workers: a cohort study of the Canadian national dose registry of radiation workers. Int J Occup Med Environ Health. 2009;22:149–156
  22. Baker SR, Bhatti WA. The thyroid cancer epidemic: is it the dark side of the CT revolution?. Eur J Radiol. 2006;60:67–69
  23. Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW. An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control. 1990;1:223–234
  24. Ron E, Kleinerman RA, Boice JD, LiVolsi VA, Flannery JT, Fraumeni JF. A population-based case–control study of thyroid cancer. J Natl Cancer Inst. 1987;79:1–12
  25. McDonald TA. A perspective on the potential health risks of PBDEs. Chemosphere. 2002;46:745–755
  26. Zuurbier M, Leijs M, Schoeters G, ten Tusscher G, Koppe JG. Children’s exposure to polybrominated diphenyl ethers. Acta Paediatr Suppl. 2006;95:65–70
  27. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg. 2005;132:840–844
  28. Passler C, Prager G, Scheuba C, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg. 2003;138:1362–1366
  29. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer. 2003;97:1181–1185
  30. Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope. 2008;118:32–38
  31. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–1264
  32. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  33. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498–512
  34. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In:  Mazzaferri EL,  Samaan N editor. Endocrine tumors. Cambridge, MA: Blackwell Scientific Publications Inc; 1993;p. 278–333
  35. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–954
  36. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–494
  37. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94:1162–1167
  38. Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg. 2007;31:2085–2091
  39. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381–387
  40. Kumar A, Bal CS. Differentiated thyroid cancer. Indian J Pediatr. 2003;70:707–713
  41. Bhattacharyya NA. population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg. 2003;128:115–123
  42. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1057
  43. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol. 1996;3:534–538
  44. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731–734
  45. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–1077
  46. Gemsenjager E, Heitz PU, Seifert B, Martina B, Schweizer I. Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years. Swiss Med Wkly. 2001;131:157–163
  47. Chiang FY, Lin JC, Lee KW, et al. Thyroid tumors with preoperative recurrent laryngeal nerve palsy: clinicopathologic features and treatment outcome. Surgery. 2006;140:413–417
  48. McCaffrey JC. Evaluation and treatment of aerodigestive tract invasion by well-differentiated thyroid carcinoma. Cancer Control. 2000;7:246–252
  49. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63:418–427
  50. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer. 2004;11:571–579
  51. Lee SH, Lee SS, Jin SM, Kim JH, Rho YS. Predictive factors for central compartment lymph node metastasis in thyroid papillary microcarcinoma. Laryngoscope. 2008;118:659–662
  52. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–5729
  53. Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006;30:1088–1095
  54. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–2899
  55. Lee J, Soh EY. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis: clinical outcomes and prognostic factors. Ann Surg. 2010;251:114–119
  56. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110:1451–1456
  57. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006;13:455–464
  58. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943–3949
  59. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 2007;246:466–470
  60. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–4090
  61. Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett. 2007;28:351–359
  62. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004;61:239–243
  63. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg. 2010;34(6):1192–1202
  64. Dottorini ME. Differentiated thyroid carcinoma in childhood. Rays. 2000;25:245–255
  65. Yeh MW, Demircan O, Ituarte P, Clark OH. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid. 2004;14:207–215
  66. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–1095
  67. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–381
  68. Bilimoria KY, Bentrem DJ, Linn JG, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142:906–913
  69. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668–3676
  70. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–260
  71. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214
  72. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554–564
  73. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81:4318–4323
  74. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229–1242
  75. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–1021
  76. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 1997;79:2414–2423
  77. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803
  78. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553–3562

PII: S0936-6555(10)00174-3

doi: 10.1016/j.clon.2010.05.004

Clinical Oncology
Volume 22, Issue 6 , Pages 395-404 , August 2010

Article Tools

* Image Usage & Resolution